[{"orgOrder":0,"company":"Toolgen","sponsor":"mCureX","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"TGT-101","moa":"VEGF","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Toolgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Toolgen \/ mCureX","highestDevelopmentStatusID":"2","companyTruncated":"Toolgen \/ mCureX"}]

Find Clinical Drug Pipeline Developments & Deals by Toolgen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Showcase
                          Not Confirmed
                          Biotech Showcase
                          Not Confirmed

                          Details : The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's TGT-101 & CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.

                          Brand Name : TGT-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 15, 2022

                          Lead Product(s) : TGT-101

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : mCureX

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank